TherVacB

New Concept to Fight Chronic Hepatitis B

Learn more

TherVacB

New Hope for Hepatitis B Patients

Learn more

TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B

European Commission and TherVacB join forces

The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.

A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.

 

The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.

About the project
b3lineicon|b3icon-lifebuoy||Lifebuoy

About TherVacB

Learn more
b3lineicon|b3icon-user-arrows||User Arrows

For Patients

Learn more
et|icon_group|

TherVacB Team

Learn more
Inken Schmütz_400x400

“I am highly pleased that for the clinical trials of TherVacB we are able to cooperate with a consortium of Europe’s leading virologists, immunologists and hepatologis. This will be of great benefit for the patients chronically infected with the hepatitis B virus."

Ulrike Protzer
Project Coordinator
Helmholtz Zentrum München

Partners

European countries

Project duration (months)

European Testing Week, 22-29 November 2021

European Testing Week, 22-29 November 2021

Nov 22, 2021 |

Get your one-off screening for hepatitis B from your GP in Germany Hepatitis B can be treated well at an early stage, hepatitis C can even be cured. In Germany, like in other countries and regions of the world, many people affected are unaware of their infection....

HBV Cure Research Community Webinar, 24th November 2021

HBV Cure Research Community Webinar, 24th November 2021

Nov 16, 2021 | ,

An online discussion for the HBV community on scientific progress in Europe towards a cure features the European HBV Patient Registry.   The International Coalition for the Elimination of HBV, ICE-HBV, in partnership with Liver Patients International open the...

Telefonsprechstunde zur Hepatitis B am 16.11.2021

Telefonsprechstunde zur Hepatitis B am 16.11.2021

Nov 11, 2021 | ,

Haben Sie Fragen zur Virushepatitis? Sprechen Sie im Rahmen einer speziellen Telefonsprechstunde zur Hepatitis B direkt mit Prof. Dr. Markus Cornberg, Erstautor der aktuellen Leitlinie zur Hepatitis B und Oberarzt an der Medizinischen Hochschule Hannover, einem der...

Animation movie

Enjoy our animation movie to understand the mission and approach of the TherVacB project!

TherVacB Project Follow 416 594

#TherVacB is a #H2020 research project developing a #therapeutic #vaccine to #cure #hepatitisB patients.

TherVacB_EU
Load More...
TherVacB